ES2156932T3 - Microparticulas cargadas con antigeno y preparados farmaceuticos que contienen estas microparticulas. - Google Patents
Microparticulas cargadas con antigeno y preparados farmaceuticos que contienen estas microparticulas.Info
- Publication number
- ES2156932T3 ES2156932T3 ES95903221T ES95903221T ES2156932T3 ES 2156932 T3 ES2156932 T3 ES 2156932T3 ES 95903221 T ES95903221 T ES 95903221T ES 95903221 T ES95903221 T ES 95903221T ES 2156932 T3 ES2156932 T3 ES 2156932T3
- Authority
- ES
- Spain
- Prior art keywords
- microparticles
- antigen
- biodegradable
- potentiation
- immunological
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
SE DESCRIBE UN PROCESO PARA LA POTENCIACION DE RESPUESTA INMUNOLOGICA EN ANTIGENOS SINTETICOS O DE INGENIERIA GENETICA DISPONIENDO DE BAJA CAPACIDAD INMUNOLOGICA. EL ANTIGENO SE ENCUENTRA EMBEBIDO DENTRO DE PARTICULAS BIODEGRADABLES, ESTANDO DISPERSAS ESTAS MICROPARTICULAS CARGADAS CON ANTIGENO EN UN MEDIO BIODEGRADABLE QUE SE DESENCADENA CUANDO ES ADMINISTRADO DE FORMA PARENTERAL EN UN ANTICUERPO POTENCIADO, CON RESPUESTA T{SUB,H} LINFOCITO Y RESPUESTA T{SUB,C} - LINFOCITO, EN COMPARACION CON UNA SOLUCION DE ANTIGENO ACUOSA. LA EXTENSION DE LA POTENCIACION INMUNOLOGICA ES AL MENOS COMPARABLE CON LA OBTENIDA POR MEDIO DE COMPOSICIONES IFA. LOS EPITOPES LINEALES B - T{SUB,T} - CELULA, EPITOPES LINEALES T{SUB,C} - CELULA, DIMEROS Y MULTIMEROS DE TALES EPITOPES, ASI COMO SUS MEZCLAS SON UTILIZADOS COMO ANTIGENOS DE BAJA CAPACIDAD INMUNOLOGICA. LAS MICROPARTICULAS SE BASAN EN BIOPOLIMEROS BIODEGRADABLES TALES COMO POLIESTER, POLIANHIDRIDO, POLIORTOESTER. MEDIANTE MEZCLADO DE MICROPARTICULAS CONDIFERENTE CAPACIDAD DE HUMECTACION, CAPACIDAD DE HINCHAMIENTO, LIBERACION Y TIEMPO DE BIODEGRADACION, SE CONSIGUE LA POTENCIACION MAS INTENSA EN DISPOSICION INMUNOLOGICA MAS LARGA. ESTE PROCESO ES UTILIZABLE PARA LA INMUNIZACION DE SERES HUMANOS Y ANIMALES CONTRA ENFERMEDADES ORIGINADAS PRO VIRUS, BACTERIAS, PROTOZOOS O CELULAS TUMORALES.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH384993 | 1993-12-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2156932T3 true ES2156932T3 (es) | 2001-08-01 |
Family
ID=4264801
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES95903221T Expired - Lifetime ES2156932T3 (es) | 1993-12-23 | 1994-12-23 | Microparticulas cargadas con antigeno y preparados farmaceuticos que contienen estas microparticulas. |
Country Status (12)
Country | Link |
---|---|
US (1) | US6596278B2 (es) |
EP (1) | EP0686030B1 (es) |
JP (1) | JPH08507088A (es) |
KR (1) | KR100372375B1 (es) |
CN (1) | CN1120809A (es) |
AT (1) | ATE199316T1 (es) |
AU (1) | AU1217395A (es) |
CA (1) | CA2156718A1 (es) |
DE (1) | DE59409668D1 (es) |
DK (1) | DK0686030T3 (es) |
ES (1) | ES2156932T3 (es) |
WO (1) | WO1995017167A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6270795B1 (en) | 1995-11-09 | 2001-08-07 | Microbiological Research Authority | Method of making microencapsulated DNA for vaccination and gene therapy |
WO1997017063A1 (en) | 1995-11-09 | 1997-05-15 | Microbiological Research Authority | Microencapsulated dna for vaccination and gene therapy |
US5783567A (en) * | 1997-01-22 | 1998-07-21 | Pangaea Pharmaceuticals, Inc. | Microparticles for delivery of nucleic acid |
US6994851B1 (en) | 1997-07-10 | 2006-02-07 | Mannkind Corporation | Method of inducing a CTL response |
US6977074B2 (en) * | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
DE69834494T2 (de) * | 1997-07-10 | 2007-03-01 | Mannkind Corp., Valencia | Vorrichtung zur induktion einer ctl-antwort |
GB9810236D0 (en) | 1998-05-13 | 1998-07-08 | Microbiological Res Authority | Improvements relating to encapsulation of bioactive agents |
US6406719B1 (en) | 1998-05-13 | 2002-06-18 | Microbiological Research Authority | Encapsulation of bioactive agents |
US6548302B1 (en) | 1998-06-18 | 2003-04-15 | Johns Hopkins University School Of Medicine | Polymers for delivery of nucleic acids |
WO2000012124A1 (en) | 1998-09-01 | 2000-03-09 | Elan Corporation, Plc | Oral vaccine compositions |
US7087236B1 (en) | 1998-09-01 | 2006-08-08 | Merrion Research I Limited | Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof |
EP2351576A1 (en) * | 2004-12-29 | 2011-08-03 | Mannkind Corporation | Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs |
CA2623197A1 (en) * | 2005-09-22 | 2007-03-29 | Prosci Incorporated | Glycosylated polypeptides produced in yeast mutants and methods of use thereof |
US20070092547A1 (en) * | 2005-10-24 | 2007-04-26 | Birnbaum Jay E | Method for treating/controlling/killing fungi and bacteria |
AU2008207025B2 (en) * | 2007-01-15 | 2012-08-23 | Glaxosmithkline Biologicals Sa | Vaccine |
US20090004213A1 (en) | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
US9408906B2 (en) | 2010-06-04 | 2016-08-09 | Flow Pharma, Inc. | Peptide particle formulation |
CN102901814B (zh) * | 2012-07-12 | 2014-11-26 | 浙江大学 | 莠去津分子印迹金标试纸条及其用途 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4599230A (en) * | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
US5762965A (en) * | 1984-03-16 | 1998-06-09 | The United States Of America As Represented By The Secretary Of The Army | Vaccines against intracellular pathogens using antigens encapsulated within biodegradble-biocompatible microspheres |
US5417986A (en) | 1984-03-16 | 1995-05-23 | The United States Of America As Represented By The Secretary Of The Army | Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres |
US4803070A (en) * | 1986-04-15 | 1989-02-07 | Ribi Immunochem Research Inc. | Immunological emulsion adjuvants for polysaccharide vaccines |
US4962091A (en) * | 1986-05-23 | 1990-10-09 | Syntex (U.S.A.) Inc. | Controlled release of macromolecular polypeptides |
US5008116A (en) * | 1988-11-14 | 1991-04-16 | Frederick Cahn | Immunostimulatory microsphere |
KR960005137B1 (ko) * | 1989-11-13 | 1996-04-22 | 노바 파머수티컬 코포레이션 | 물질 전달용 리포스피어 |
WO1992019263A1 (en) * | 1991-04-24 | 1992-11-12 | The United States Of America, As Represented By The Secretary Of The Army | Oral-intestinal vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres |
FR2695563B1 (fr) * | 1992-09-11 | 1994-12-02 | Pasteur Institut | Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires. |
US6004763A (en) | 1992-09-11 | 1999-12-21 | Institut Pasteur | Antigen-carrying microparticles and their use in the induction of humoral or cellular responses |
WO1994015635A1 (en) * | 1993-01-11 | 1994-07-21 | Dana-Farber Cancer Institute | Inducing cytotoxic t lymphocyte responses |
US5879687A (en) * | 1994-04-22 | 1999-03-09 | Corixa Corporation | Methods for enhancement of protective immune responses |
PT991403E (pt) | 1997-01-30 | 2003-08-29 | Chiron Corp | Uso de microparticulas com antigenio adsorvido para estimular respostas imunes |
EP1009386B1 (en) | 1997-08-29 | 2005-08-31 | Corixa Corporation | Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of using thereof |
ATE215385T1 (de) | 1997-12-16 | 2002-04-15 | Chiron Corp | Verwendung von mikropartikeln mit submikron öl/wasser emulsionen |
EP1107783B1 (en) | 1998-09-01 | 2006-04-05 | ELAN CORPORATION, Plc | Method for inducing a cell-mediated immune response and parenteral vaccine formulations therefor |
-
1994
- 1994-12-23 JP JP7517077A patent/JPH08507088A/ja not_active Ceased
- 1994-12-23 EP EP95903221A patent/EP0686030B1/de not_active Expired - Lifetime
- 1994-12-23 WO PCT/CH1994/000242 patent/WO1995017167A1/de active IP Right Grant
- 1994-12-23 KR KR1019950703557A patent/KR100372375B1/ko not_active IP Right Cessation
- 1994-12-23 DK DK95903221T patent/DK0686030T3/da active
- 1994-12-23 AU AU12173/95A patent/AU1217395A/en not_active Abandoned
- 1994-12-23 AT AT95903221T patent/ATE199316T1/de not_active IP Right Cessation
- 1994-12-23 CN CN94191709A patent/CN1120809A/zh active Pending
- 1994-12-23 US US08/507,323 patent/US6596278B2/en not_active Expired - Fee Related
- 1994-12-23 ES ES95903221T patent/ES2156932T3/es not_active Expired - Lifetime
- 1994-12-23 CA CA002156718A patent/CA2156718A1/en not_active Abandoned
- 1994-12-23 DE DE59409668T patent/DE59409668D1/de not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP0686030B1 (de) | 2001-02-28 |
ATE199316T1 (de) | 2001-03-15 |
KR960700692A (ko) | 1996-02-24 |
WO1995017167A1 (de) | 1995-06-29 |
US6596278B2 (en) | 2003-07-22 |
CN1120809A (zh) | 1996-04-17 |
JPH08507088A (ja) | 1996-07-30 |
DE59409668D1 (de) | 2001-04-05 |
CA2156718A1 (en) | 1995-06-29 |
KR100372375B1 (ko) | 2003-04-21 |
DK0686030T3 (da) | 2001-06-25 |
AU1217395A (en) | 1995-07-10 |
US20020041879A1 (en) | 2002-04-11 |
EP0686030A1 (de) | 1995-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2156932T3 (es) | Microparticulas cargadas con antigeno y preparados farmaceuticos que contienen estas microparticulas. | |
AU7980794A (en) | Methods and compositions for microencapsulation of antigens for use as vaccines | |
Stacey et al. | Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major | |
DK0678034T3 (da) | Induktion af cytotoksiske T-lymfocytreaktioner | |
CA2172507A1 (en) | Methods and compositions for microencapsulation of antigens for use as vaccines | |
DE69810459T2 (de) | Reagenzien zur impfung, die eine cd8 t-zell-immunantwort erzeugen | |
CA2033640A1 (en) | Vaccines against cancer and infectious diseases | |
FI933328A0 (fi) | Antigen producerande protein | |
DE60117978D1 (de) | Modifizierung des hepatitis b kernantigens | |
WO2001079259A8 (en) | Javelinization of protein antigens to heat shock proteins | |
KR100218138B1 (en) | Methods and vaccines comprising surface-active copolymers | |
EP2057999A3 (en) | Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines | |
DE3854591D1 (de) | Impfstoffe, deren charakteristischer Epitop in einem Picornavirusprotein, insbesondere Poliovirus, inkorporiert ist. | |
CA2137363A1 (en) | Use of Zona Pellucida Glycoproteins for Immunocontraception | |
CA2128247A1 (en) | Vaccines based on streptokinase | |
CA2133108A1 (en) | Pasteurella haemolytica type a-1 bacterin-toxoid vaccine | |
Lovgren | Construction and potential of the iscom as immunogen. | |
YouNG-RoDENCHUK et al. | Differences in the sensitivity of tumor cells and normal lymphocytes toward lysis by alloantibodies and guinea pig or rabbit complement | |
HU9900534D0 (en) | Aviadenovirus | |
Edgington | Immune responses and liver disease, perhaps. But what about target organ defenses? | |
Barber | Antigenic structure of Salmonella paratyphi A grown on artificial media. | |
Zourbas et al. | Immunization of dental surgeons against hepatitis B virus infection. | |
Fedorovskaya et al. | Immune response of the body of donors to pyocyaneus antigen formerly hyperimmunized with staphylococcal anatoxine. | |
LV12736A (en) | Method for producing concentrated antigen composition against swine erysipelas disease | |
RU93008069A (ru) | Способ иммунизации крупного рогатого скота |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 686030 Country of ref document: ES |